2 results
Approved WMOCompleted
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
Approved WMOCompleted
Our hypothesis is that continuous intravenous glucose monitoring is helpful in ICU patients treated with IIT to:a) reach and maintain the glucose-target of 4.4-6.1 mmol/L soonerb) to increase safety, by eliminating the development of hypoglycaemiac…